Impact of polymorphisms in drug pathway genes on disease-free survival in adults with acute myeloid leukemia

Sook Wah Yee, Joel A. Mefford, Natasha Singh, Mary Elizabeth Percival, Adrian Stecula, Kuo Yang, John S. Witte, Atsushi Takahashi, Michiaki Kubo, Koichi Matsuda, Kathleen M. Giacomini, Charalambos Andreadis

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Acute myeloid leukemia (AML) is a clinically heterogeneous disease, with a 5-year disease-free survival (DFS) ranging from under 10% to over 70% for distinct groups of patients. At our institution, cytarabine, etoposide and busulfan are used in first or second remission patients treated with a two-step approach to autologous stem cell transplantation (ASCT). In this study, we tested the hypothesis that polymorphisms in the pharmacokinetic and pharmacodynamic pathway genes of these drugs are associated with DFS in AML patients. A total of 1659 variants in 42 genes were analyzed for their association with DFS using a Cox-proportional hazards model. One hundred and fifty-four genetically European patients were used for the primary analysis. An intronic single nucleotide polymorphism (SNP) in ABCC3 (rs4148405) was associated with a significantly shorter DFS (hazard ratios (HR)=3.2, P=5.6 × 10-6) in our primary cohort. In addition, a SNP in the GSTM1-GSTM5 locus, rs3754446, was significantly associated with a shorter DFS in all patients (HR=1.8, P=0.001 for 154 European ancestry; HR=1.7, P=0.028 for 125 non-European patients). Thus, for the first time, genetic variants in drug pathway genes are shown to be associated with DFS in AML patients treated with chemotherapy-based autologous ASCT.

Original languageEnglish
Pages (from-to)353-361
Number of pages9
JournalJournal of Human Genetics
Volume58
Issue number6
DOIs
Publication statusPublished - 01-06-2013

All Science Journal Classification (ASJC) codes

  • Genetics
  • Genetics(clinical)

Fingerprint Dive into the research topics of 'Impact of polymorphisms in drug pathway genes on disease-free survival in adults with acute myeloid leukemia'. Together they form a unique fingerprint.

  • Cite this

    Yee, S. W., Mefford, J. A., Singh, N., Percival, M. E., Stecula, A., Yang, K., Witte, J. S., Takahashi, A., Kubo, M., Matsuda, K., Giacomini, K. M., & Andreadis, C. (2013). Impact of polymorphisms in drug pathway genes on disease-free survival in adults with acute myeloid leukemia. Journal of Human Genetics, 58(6), 353-361. https://doi.org/10.1038/jhg.2013.38